Viking Therapeutics, Inc. (VKTX)

$68.48

-0.37

(-0.54%)

Market is closed - opens 8 PM, 11 Nov 2024

Performance

  • $65.77
    $70.36
    $68.48
    downward going graph

    3.96%

    Downside

    Day's Volatility :6.52%

    Upside

    2.67%

    downward going graph
  • $9.34
    $99.41
    $68.48
    downward going graph

    86.36%

    Downside

    52 Weeks Volatility :90.6%

    Upside

    31.11%

    downward going graph

Returns

PeriodViking Therapeutics, Inc.
3 Months
17.28%
6 Months
-5.35%
1 Year
589.63%
3 Years
997.44%

Highlights

Market Capitalization
7.3B
Book Value
$8.18
Earnings Per Share (EPS)
-0.94
PEG Ratio
-0.03
Wall Street Target Price
117.36
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-12.68%
Return On Equity TTM
-15.5%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-0.94
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.98
EPS Estimate Next Year
-1.51
EPS Estimate Current Quarter
-0.25
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Viking Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
15
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 71.38%

Current $68.48
Target $117.36

Technicals Summary

Sell

Neutral

Buy

Viking Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
4.01%
-5.35%
589.63%
997.44%
789.35%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.44%
-15.2%
3.98%
32.2%
140.62%
Biontech Se
Biontech Se
-8.2%
19.33%
12.98%
-53.1%
460.49%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-2.42%
85.09%
68.13%
60.32%
200.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
7.27%
20.19%
36.37%
178.01%
155.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
NA
NA
-0.03
-0.98
-0.15
-0.13
NA
8.18
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.41
20.41
1.2
44.89
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.1
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.13
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
Buy
$7.3B
789.35%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
140.62%
20.41
33.61%
Biontech Se
Biontech Se
Buy
$25.9B
460.49%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.1B
200.09%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.9B
155.94%
32.84
-4.51%

Institutional Holdings

  • FMR Inc

    14.84%
  • Vanguard Group Inc

    9.06%
  • BlackRock Inc

    5.41%
  • State Street Corp

    4.60%
  • JPMorgan Chase & Co

    2.02%
  • Morgan Stanley - Brokerage Accounts

    1.70%

Corporate Announcements

  • Viking Therapeutics, Inc. Earnings

    Viking Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

novel therapeutics for metabolic and endocrine disorders.

Organization
Viking Therapeutics, Inc.
Employees
30
CEO
Dr. Brian Lian Ph.D.
Industry
Health Technology

FAQs